[A26-02] Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Addendum to Project A25-108
Last updated 19.02.2026
Project no.:
A26-02
Commission:
Commission awarded on 13.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Result of dossier assessment:
After addendum now: hint of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-02
| Project no. | Title | Status |
|---|---|---|
| A25-108 | Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
19-02-2026 A G-BA decision was published.
G-BA documents on this decision